INTENT TO SOLE SOURCE AEMS Think Trends Licenses (Brand Name)
Closed Special Notice Posted
- Solicitation number
- FDA-75F40126Q00384
- Agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541519 Other Computer Related Services
- Place of performance
- Silver Spring, Maryland 20993, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The FDA Office of Acquisition and Grant Services issued an intent to sole source Think Trends Software Licenses to ThinkTrends, LLC under FAR 6.302-1, with capability statements due by September 9, 2026, at 1:00 PM Eastern Standard Time.
The FDA Centers and Offices require Think Trends licenses to reduce manual case-processing burden, improve extraction accuracy, accelerate regulatory review workflows, and support Center-specific adverse event reporting requirements. The solution delivers configurable AI agents, human-in-the-loop validation, auditability, and secure deployment within FDA-approved environments. The government asserts that the proposed source possesses sole unique technical and other resources required for this acquisition.
ThinkTrends, LLC is located at 171 Elden Street, Suite 3C1, Herndon, Virginia 20170. The contract period of performance is one year on a firm fixed-price basis. The classification is DA10 (IT and Telecom—Business Application/Application Development Software as a Service) under NAICS 541519 (Other Computer Related Services).
Interested parties who believe they can meet the requirement may submit a capability statement to Terina Hicks at terina.hicks@fda.hhs.gov. No telephonic inquiries are accepted. If no responsive statements are received by the closing date and time, an award will be made to ThinkTrends, LLC.
Notice text
The FDA Centers and Offices requires Think Trends Software Licenses to reduce manual case-processing burden, improve extraction accuracy, accelerate regulatory review workflows, and support Center-specific adverse event reporting requirements through configurable AI agents, human-in-the-loop validation, auditability, and secure deployment within FDA-approved environments. The proposed source has the sole unique technical and other resources required for this acquisition. This will be a one-year period of performance.
Files
| File | Type | Posted |
|---|---|---|
| Intent to Sole Source FDA-75F40126Q00384.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity